Is Johnson & Johnson a Buy?
It may be surprising to hear that coronavirus vaccine maker Johnson & Johnson (NYSE: JNJ) has significantly underperformed the market over the past year. Indeed, during that period, the pharma giant's stock only went up a meager 12%, far less than the S&P 500 index's mouth-watering 30% gain. This has left many investors wondering: Why?
As it turns out, the golden age of investing in coronavirus vaccine stocks is mostly over. Now's the time for coronavirus vaccine manufacturers to show that they can turn reliable profits with what they developed. Can Johnson & Johnson accomplish that goal?
Image source: Getty Images.
Source Fool.com
